logo

Clinical Trial Results

Share

Eli Lilly and Company (LLY) said, in a Phase 4 IXORA-R study, Taltz met the primary endpoint of superiority compared to TREMFYA in the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance at Week 12, as well as key secondary endpoints. The safety profiles...

Shares of Catabasis Pharmaceuticals Inc. (CATB) are up over 5% in premarket trading on Tuesday, following the completion of enrollment in the Company's phase III trial of Edasalonexent in Duchenne muscular dystrophy.

AstraZeneca (AZN.L, AZN) and Merck & Co., Inc. said that Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer. AstraZeneca and Merck's Lynparza reduced the risk of disease progression or...

Novartis (NVS) said that Kisqali delivered consistently superior overall survival. The MONALEESA-3 trial on Kisqali demonstrated more life for postmenopausal HR+/HER2- advanced breast cancer patients. In MONALEESA-3 trial, Kisqali plus fulvestrant achieved statistically significant overall survival...

Jazz Pharmaceuticals plc (JAZZ) presented positive data from its Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy. The results from the trial were reported by the company on March 26, 2019.

ancoraheartinc-092619.jpg Ancora Heart Inc., a privately-held medical device company, on Wednesday said that its investigational non-surgical heart failure therapy AccuCinch Ventricular Repair System for the treatment of systolic heart failure showed positive results in its study dubbed CorCinch FMR.

Enanta Pharmaceuticals, Inc. (ENTA) on Wednesday said its Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH), dubbed ARGON-1, achieved its primary and secondary endpoints.

Acceleron Pharma Inc. (XLRN) on Monday said its investigational therapy ACE-083 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) did not achieve functional secondary endpoints in the Phase 2 trial.

AVITA Medical (AVMXY.OB) on Monday announced that the FDA has approved the company's Investigational Device Exemption (IDE) application to conduct a study of the Autologous Cell Harvesting Device RECELL in combination with meshed autografting for the treatment of acute soft tissue injuries, defects, and reconstruction.

The emerging durability data were from the cohort of treatment-naïve wet AMD patients, and all the patients achieved a treatment-free interval of three months or longer, with the majority reaching a four- or five-month interval and continuing to be followed without retreatment to date.

Follow RTT
>